Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Definitions

• the present invention relates to a mucoadhesive tablet comprising pregabalin with pharmaceutically acceptable excipients, wherein the mucoadhesive tablet maintains gastric retention for the time period during which the drug is released into the stomach. Further it relates to a process for the preparation of the mucoadhesive tablet
• Pregabalin is an analogue of the physiologically important endogenous neurotransmitter [gamma] -amino butyric acid (GABA), which is involved in the regulation of neural processes.
• GABA physiologically important endogenous neurotransmitter
• Pregabalin is disclosed in U.S. Patent Nos. 6,197,819 and 5,563,175, which describe its use in the treatment of seizure disorders.
• U.S. Patent No. 6,117,906 discloses the use of pregabalin in treating anxiety, while U.S. Patent No. 6,001 ,876 discloses its use in treating pain.
• pregabalin is available as conventional immediate-release capsules marketed by CP Pharms/Pfizer under the brand name Lyrica ® .
• Lyrica ® Capsules requires two or three times a day dosing.
• a once-daily tablet is desirable.
• pregabalin cannot be absorbed in the entire gastrointestinal tract (GIT).
• GIT gastrointestinal tract
• Pregabalin is only absorbed in the upper sections of the gut. It is therefore desirable to have a dosage form which has a longer retention time in the upper GIT and which, during that time, releases the active agent continuously over a longer period of time.
• the U.S. Publication Application No. 2007/0269511 discloses a pregabalin formulation containing matrix forming agent and a swelling agent, wherein the matrix forming agent is polyvinyl acetate and polyvinylpyrrolidone, and the swelling agent is cross-linked polyvinylpyrrolidone.
• the U.S. Publication Application No. 2010/0255067 describes pharmaceutical compositions comprising pregabalin, a hydrophobic release controlling agent, and other pharmaceutically acceptable excipients.
• the U.S. Publication Application No. 2013/149253 describes oral dosage form for the modified release of pregabalin, comprising pregabalin in a matrix comprising a swelling agent, a matrix former and a buoyancy agent or alternatively a sedimentation agent. Therefore, a mucoadhesive tablet that retains in the upper parts of the gastrointestinal tract would be an ideal dosage form for pregabalin.
• the objective of the present invention is to develop a mucoadhesive tablet of pregabalin.
• the primary object of the invention is to provide a mucoadhesive tablet comprising pregabalin with pharmaceutically acceptable excipients, wherein the mucoadhesive tablet maintains gastric retention for the time period during which the drug is released into the stomach.
• Another object of the invention is to provide a mucoadhesive tablet comprising pregabalin with at least mucoadhesive excipient, at least one swelling agent and at least one gelling agent, wherein the mucoadhesive tablet maintains gastric retention for the time period during which the drug is released into the stomach.
• Another object of the invention is to provide a process for the preparation of a mucoadhesive tablet of pregabalin.
• the invention relates to a mucoadhesive tablet comprising pregabalin with pharmaceutically acceptable excipients, wherein the mucoadhesive tablet maintains gastric retention for the time period during which the drug is released into the stomach.
• the invention in another embodiment, relates to a mucoadhesive tablet comprising pregabalin with at least mucoadhesive excipient, at least one swelling agent and at least One gelling agent, wherein the mucoadhesive tablet maintains gastric retention for the time period during which the drug is released into the stomach.
• the invention relates to a mucoadhesive tablet comprising pregabalin with polyethylene oxide (PEO) as mucoadhesive excipient, cross-linked homopolymers of l-vinyl-pyrrolidin-2-one (Crospovidone) as swelling agent, and sodium alginate as gelling agent.
• PEO polyethylene oxide
• Cross-linked homopolymers of l-vinyl-pyrrolidin-2-one (Crospovidone) as swelling agent
• sodium alginate sodium alginate
• the invention relates to a mucoadhesive tablet comprising pregabalin with tragacanth as mucoadhesive excipient, sodium starch glycolate as swelling agent, and polymers of acrylic acid cross-linked with polyalkenyl ethers or divinyl glycol such as carbomers (carbopols) as gelling agent.
• the invention relates to a process for the preparation of a mucoadhesive tablet of pregabalin, preferably direct compression method.
• the present invention relates to a mucoadhesive tablet comprising pregabalin with pharmaceutically acceptable excipients, wherein the mucoadhesive tablet maintains gastric retention for the time period during which the drug is released into the stomach.
• the "mucoadhesive tablet” remains in the patient's stomach following oral administration, which is substantially longer than the average residence time of a corresponding immediate release dosage form.
• the present invention may employ any pharmaceutically acceptable form of pregabalin, including its free form (zwitter ion), and its pharmaceutically acceptable complexes, acid addition salts, base addition salts solvates, hydrates, and polymorphs.
• the present invention relates to a mucoadhesive tablet comprising pregabalin with at least mucoadhesive excipient, at least one swelling agent and at least one gelling agent, wherein the mucoadhesive tablet maintains gastric retention for the time period during which the drug is released into the stomach.
• the "mucoadhesive excipient" of the present invention includes polyethylene glycol (PEG 8000), Tragacanth, polymethacrylate derivatives (Eudragit), polyethylene oxide (PEO) or combinations or copolymers thereof.
• the mucoadhesive excipient is generally used in an amount ranging from about 5% to about 20% by weight of the tablet composition .
• the "swelling agent" of the present invention includes croscarmellose sodium, sodium starch glycolate (SSG), microcrystalline cellulose (MCC), starch, cross- linked homopolymers of 1 -vinyl-pyrrolidin-2-one (Crospovidone) or combinations or copolymers thereof.
• the swelling agent absorbs water from the gastric fluid and thereby the tablet expands in size larger than the pylorus.
• the swelling agent is generally used in an amount ranging from about 5% to about 30% by weight of the tablet composition.
• the "gelling agent" of the present invention includes polyvinyl pyrrol idone (PVP), polymers of acrylic acid cross-linked with polyalkenyl ethers or divinyl glycol such as carbomers (carbopols), alginates, preferably sodium alginate, hydroxyalkyl cellulose, especially hydroxyethyl cellulose (HEC), xanthan gum or combinations or copolymers thereof.
• PVP polyvinyl pyrrol idone
• carbomers carbomers
• alginates preferably sodium alginate
• hydroxyalkyl cellulose especially hydroxyethyl cellulose (HEC)
• HEC hydroxyethyl cellulose
• xanthan gum xanthan gum or combinations or copolymers thereof.
• the gelling agent includes excipient that forms a gel when in contact with gastric fluid and thereby modulates the drug release characteristics of the tablet.
• the gelling agent is generally used in an amount ranging from about 0.5% to about 40% by weight
• the mucoadhesive tablet may also comprise further pharmaceutically acceptable excipients such as diluents, binders, rate-controlling agents, lubricants, wetting agent, glidants and coating excipients.
• excipients such as diluents, binders, rate-controlling agents, lubricants, wetting agent, glidants and coating excipients.
• the mucoadhesive tablet of pregabalin is designed for once-daily administration and achieves bioequivalence with immediate release dosage form of pregabalin that is taken two- or three-times daily.
• the invention in another embodiment, relates to a process for the preparation of a mucoadhesive tablet of pregabalin. It can be prepared by routine tableting method including direct compression, granulation and pelletization methods. Preferably, the process for the preparation is direct compression method.
• Example 1 Mucoadhesive Tablet by Direct Compression approach
• the mucoadhesive tablet of the present invention is prepared by Direct Compr method in the procedural steps as described below. Manufacturing Process:

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=53757863

Family Applications (1)

Country Status (2)

Cited By (2)

Family Cites Families (1)

• 2015
  • 2015-01-20 IN IN215MU2014 patent/IN2014MU00215A/en unknown
  • 2015-01-20 WO PCT/IN2015/000033 patent/WO2015114656A2/en not_active Ceased

Also Published As

Similar Documents

Legal Events